{"id":4051,"date":"2026-11-03T09:00:00","date_gmt":"2026-11-03T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4051"},"modified":"2026-11-03T22:18:33","modified_gmt":"2026-11-04T02:18:33","slug":"calr-mutant-mpns-show-a-tigit-positive-nk-cell-state","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4051","title":{"rendered":"CALR Mutant MPNs Show a TIGIT Positive NK Cell State"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Witalisz-Siepracka laboratory (academic)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-reviewed publication<\/p>\n

Modality<\/strong><\/p>\n

Checkpoint (TIGIT) blockade hypothesis<\/p>\n

Asset<\/strong><\/p>\n

Anti-TIGIT (preclinical, mouse model)<\/p>\n

Target<\/strong><\/p>\n

TIGIT; CD112<\/p>\n

Disease Area<\/strong><\/p>\n

CALR-mutant myeloproliferative neoplasms (ET, myelofibrosis)<\/p>\n

Summary<\/h4>\n

A peer-reviewed Leukemia paper published online November 3 reports preserved natural killer (NK) cell degranulation in CALR-mutant myeloproliferative neoplasms (MPNs), alongside elevated TIGIT on patient NK cells and CD112 on patient CD34-positive cells. TIGIT blockade reduced platelet counts in a transplant mouse model. This is a mechanistic treatment hypothesis, not clinical efficacy.<\/p>\n

The investigators compared CALR-mutant and JAK2-mutant patient samples and a CALR-mutant mouse model. CALR-mutant patient NK cells degranulated more than JAK2-mutant counterparts but expressed high TIGIT. The authors link this checkpoint state to ligand-expressing target cells and report a mouse pharmacology signal.<\/p>\n

Deep Analysis<\/h4>\n

Inference A:<\/strong> TIGIT may restrain otherwise capable NK cells in CALR-mutant MPN. Human phenotype, CD112 expression, and mouse blockade support this. Counterevidence: phenotype is associative, and platelet lowering is not proof of malignant-clone clearance. Inference B:<\/strong> TIGIT marks chronic immune activation without being the dominant therapeutic bottleneck. This fits the patient-level association and cross-species uncertainty, but the intervention in mice argues against a purely passive marker. The decisive experiments are patient-derived killing assays, clone-specific response, dose-response and safety, and durable mutant-allele-burden reduction in a disease-relevant model.<\/p>\n

Company and Product Background<\/h4>\n

CALR frameshift mutations activate MPL\u2013JAK signaling in a subset of MPNs, including ET and MF. TIGIT is an inhibitory receptor on NK and T cells; CD112 can serve as a ligand. Restoring NK recognition is the proposed mechanism.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • This study nominates a genotype-stratified immunotherapy avenue for essential thrombocythemia and myelofibrosis associated with CALR mutations.<\/li>\n
  • Translation must address target specificity, effects on normal hematopoiesis, cytokine risk, tissue access, and whether platelet reduction reflects disease modification.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The paper strengthens the rationale for testing TIGIT biology in CALR-mutant MPN, with moderate mechanistic confidence and low treatment-readiness. Clinical benefit remains untested.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high for published experiments. Confidence in Interpretation: moderate for mechanism, low for therapy. Missing: human intervention data, marrow-specific pharmacology, long-term safety.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A peer-reviewed Leukemia paper published online November 3 reports preserved natural killer (NK) cell degranulation in CALR-mutant myeloproliferative neoplasms (MPNs), alongside elevated TIGIT on patient NK cells and CD112 on patient CD34-positive cells. TIGIT…<\/p>\n","protected":false},"author":1,"featured_media":4053,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1348,1351,115,1350,1349],"class_list":["post-4051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-calr","tag-leukemia","tag-myeloproliferative-neoplasms","tag-nk-cells","tag-tigit"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4051"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4051\/revisions"}],"predecessor-version":[{"id":4061,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4051\/revisions\/4061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4053"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}